Volume 3, Supplement 2SupplementProstate Cancer: Risk Assessment and Diagnostic ApproachesMichael K BrawerLeonard G GomellaFernand LabrieEduard J GamitoProstate cancerProstate biopsyIGF-ISusceptibility genesTransrectal
Volume 3, Supplement 2SupplementTherapeutic Strategies for Localized Prostate CancerE David CrawfordLeonard G GomellaDaniel P PetrylakJoseph BatuelloAndrew B JoelJoel KaufmanJohn LynchProstate cancerErectile dysfunctionHormonal therapyProstatectomy, radical
Volume 7, Supplement 5Review ArticlesAddressing the Needs of the High-Risk Prostate Cancer PatientLeonard G GomellaHormonal therapyRadiation therapyProstate cancer, high risk
Volume 11, Number 2Review ArticlesEffective Testosterone Suppression for Prostate Cancer: Is There a Best Castration Therapy?Management UpdateLeonard G GomellaAchieving and maintaining effective suppression of serum testosterone levels in men treated with androgen ablation is one of the essential strategies in the management of prostate cancer. Historically, a serum testosterone below 50 ng/dL was considered to be the castrate level. Current data suggest that the new target for either surgical or chemical castration is a serum testosterone level of lower than 20 ng/dL in an attempt to maximize therapeutic outcomes. Testosterone breakthrough and the acute-on-chronic effects of administration of a luteinizing hormone-releasing hormone analogue may cause testosterone levels to periodically rise, sometimes to noncastrate levels. The goal of androgen ablation is to identify those agents that will most consistently achieve and maintain the lowest testosterone levels possible.[Rev Urol. 2009;11(2):52-60]Prostate cancerAndrogen ablationLHRH analoguesLHRH antagonists